FABP5 and myeloid sarcoma: In EAE, FABP5 deficiency resulted in reduced production of pro-inflammatory cytokines and reduced differentiation of Th17 and Th1 cells [59], an effect that was recapitulated using a FABP5 inhibitor, suggesting that FABP inhibition could be a novel therapeutic strategy in MS [60, 61].